Publication details
PSIKET DEVELOPMENT SAFETY UPDATE REPORT Psilocybin versus ketamin – strategie rychlé antidepresivní odpovědi u deprese rezistentní k léčbě Období: 22.3.2023 – 21.3.2024
| Title in English | PSIKET DEVELOPMENT SAFETY UPDATE REPORT Psilocybin versus ketamine – a strategy for rapid antidepressant response in treatment-resistant depression Period: 22.3.2023 – 21.3.2024 |
|---|---|
| Authors | |
| Year of publication | 2024 |
| MU Faculty or unit | |
| web | |
| Description | The second periodic report for the PSIKET_001CZE study evaluates the safety data received by the study sponsor during the period from 22.3.2023 to 21.3.2024. The clinical trial is a monocentric trial with a center at the National Institute of Mental Health in the Czech Republic. The PSIKET clinical trial is focused on studying the antidepressant effect of the natural alkaloid psilocybin in a population of patients with pharmacoresistant depression. The effect is compared with control substances with acute short-term antidepressant effect (with ketamine) and without antidepressant effect (with midazolam). |